A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers

Objective: Infection with hepatitis C virus is the leading indication for liver transplantation and most common cause of infectious disease-related mortality in the United States. BZF961 is a novel inhibitor of the hepatitis C virus NS3-4A protease. Methods: This sequential, three part exploratory f...

Descripción completa

Detalles Bibliográficos
Autores principales: Youngberg, Stephen, Brandt, Erin, Barve, Avantika, Machineni, Surendra, Jones, Christopher T., Dabovic, Kristina, Jones, Catherine L., Colvin, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201795/
https://www.ncbi.nlm.nih.gov/pubmed/30370176
http://dx.doi.org/10.1080/21556660.2018.1535438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201795/
https://www.ncbi.nlm.nih.gov/pubmed/30370176
http://dx.doi.org/10.1080/21556660.2018.1535438

Ejemplares similares